Article

The Differential Effect of Carbon Dots on Gene Expression and DNA Methylation of Human Embryonic Lung Fibroblasts as a Function of Surface Charge and Dose

Michal Sima 1, Kristyna Vrbova 1, Tana Zavodna 2, Katerina Honkova 2, Irena Chvojkova 2, Antonin Ambroz 1, Jiri Klema 3, Andrea Rossnerova 2, Katerina Polakova 4, Tomas Malina 4,5, Jan Belza 4,5, Jan Topinka 2 and Pavel Rossner, Jr. 1,*

1 Department of Nanotoxicology and Molecular Epidemiology, Institute of Experimental Medicine of the Czech Academy of Sciences, 14220 Prague, Czech Republic; michal.sima@iem.cas.cz (M.S.); kristyna.vrbova@iem.cas.cz (K.V.); antonin.ambroz@iem.cas.cz (A.A.)
2 Department of Genetic Toxicology and Epigenetics, Institute of Experimental Medicine of the Czech Academy of Sciences, 14220 Prague, Czech Republic; tana.brzicova@iem.cas.cz (T.Z.); katerina.honkova@iem.cas.cz (K.H.); irena.chvojkova@iem.cas.cz (I.C.); andrea.rossnerova@iem.cas.cz (A.R.); jan.topinka@iem.cas.cz (J.T.)
3 Department of Computer Science, Czech Technical University in Prague, 12135 Prague, Czech Republic; klema@fel.cvut.cz
4 Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University Olomouc, 77146 Olomouc, Czech Republic; katerina.polkova@upol.cz (K.P.); tomas.malina@upol.cz (T.M.); jan.belza01@upol.cz (J.B.)
5 Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, 77146 Olomouc, Czech Republic

* Correspondence: pavel.rossner@iem.cas.cz; Tel.: +420-241-062-763

Received: 28 May 2020; Accepted: 2 July 2020; Published: 4 July 2020

Abstract: This study presents a toxicological evaluation of two types of carbon dots (CD), similar in size (<10 nm) but differing in surface charge. Whole-genome mRNA and miRNA expression (RNAseq), as well as gene-specific DNA methylation changes, were analyzed in human embryonic lung fibroblasts (HEL 12469) after 4 h and 24 h exposure to concentrations of 10 and 50 µg/mL (for positive charged CD; pCD) or 10 and 100 µg/mL (for negative charged CD, nCD). The results showed a distinct response for the tested nanomaterials (NMs). The exposure to pCD induced the expression of a substantially lower number of mRNAs than those to nCD, with few commonly differentially expressed genes between the two CDs. For both CDs, the number of deregulated mRNAs increased with the dose and exposure time. The pathway analysis revealed a deregulation of processes associated with immune response, tumorigenesis and cell cycle regulation, after exposure to pCD. For nCD treatment, pathways relating to cell proliferation, apoptosis, oxidative stress, gene expression, and cycle regulation were detected. The expression of miRNAs followed a similar pattern: more pronounced changes after nCD exposure and few commonly differentially expressed miRNAs between the two CDs. For both CDs the pathway analysis based on miRNA-mRNA interactions, showed a deregulation of cancer-related pathways, immune processes and processes involved in extracellular matrix interactions. DNA methylation was not affected by exposure to any of the two CDs. In summary, although the tested CDs induced distinct responses on the level of mRNA and miRNA expression, pathway analyses revealed a potential common biological impact of both NMs independent of their surface charge.

Keywords: carbon dots; surface charge; human lung fibroblasts; gene expression; DNA methylation
1. Introduction

Carbon dots (CDs) belong to a relatively new class of nanomaterials with a size smaller than 10 nm but with a large surface area. CDs were first isolated from crude soot in 2004 [1], after which many similar carbon substances were discovered. Due to CDs’ high biocompatibility, photostability, and photoluminescence, they have been used in biomedicine for bioimaging or drug delivery (reviewed by Duran et al. [2]). It has also been shown that the CDs’ surface area allows ligand binding, influencing the behavior of the material, such as trafficking in cells, cellular uptake and cytotoxicity (reviewed by Zhao et al. [3]).

The toxicity of carbon dots has so far been mostly evaluated using the detection of ROS production, cell viability, and cell cycle changes. Thus, Tao et al. [4] showed no viability changes in human kidney embryonic T293T cells, exposed to three different carbon nanoparticles. Other studies have indicated that the cytotoxicity of CDs might be connected with the surface passivation type and not to the CDs themselves [5,6]. Havrdova et al. [7] tested the cytotoxicity of CDs derived from candle soot with three divergent surface functionalization: pristine with negative charge, polyethylene glycol with neutral charge, and polyethyleneimine with positive charge. The effects in in vitro experiments on the standard mouse fibroblasts (NIH/3T3) also varied based on the CD surface charges. Nanoparticles differently influenced the cell cycle, cell morphology, intracellular trafficking, or ROS production. Neutrally charged CDs were the least toxic. The results confirmed that the cytotoxicity was caused by the type of surface modification [7].

The cytotoxic effects of the nanoparticles were also shown to be cell specific. Hsu et al. [8], exposed three various human cancer and two normal control cell lines to carbon dots. A high viability decrease was only observed in the cancer cells and did not appear in the controls. Similarly, high toxicity was observed in human hepatocellular carcinoma cells (HepG2), but not in normal liver cells (FL83B) treated with fluorescent carbon nanodots [9].

In contrast to toxicity markers studied for various types of carbon dots and cell lines, the research focused on gene expression changes due to CDs exposure is sparse. CDs affected the expression of genes encoding antioxidant enzymes via scavenging reactive oxygen species, in rodent mesenchymal stem cells [10]. Li et al. [11] reported expression changes in genes associated with cell cycle progression, cytoskeleton maintenance, or DNA repair in human esophageal epithelial cells exposed to CDs. In human umbilical cord cells and fibroblasts derived from neonatal foreskin, the genes associated with proangiogenic factors were deregulated after exposure to CDs prepared from citric acid and urea [12]. Next generation sequencing of whole genome gene expression changes, after exposure to carbon dots, have so far only been studied in plants. The deregulation of genes responsible for oxidative stress, photosynthetic processes, and the osmotic potential, was observed in Arabidopsis thaliana treated with 3 nm CDs [13].

To date, three studies describing the utilization of the positive charged quaternized CDs (pCD) have been published. Maiti et al. [14] hybridized pCDs with DNA and bound these structures to histones, which enabled their sensitive detection by fluorescence monitoring. For the first time, Datta et al. [15] imported these CDs in the cell nucleus of mouse fibroblasts (NIH/3T3) and showed no cell viability changes after using the concentration necessary for cell imaging. Malina et al. [16] used pCDs as a novel stem cell tracking probe in in vivo experiments with transplanted human mesenchymal stromal cells. They described high biocompatibility by studying in vitro toxicity. Based on the results of ROS production, cell viability, cell cycle changes, and DNA breaks assessed by comet assay, pCDs in concentration applicable for imaging, have not been found to cause any negative effects on the native function and behavior of the stromal cells [16].

In this study, we compared the cytotoxic effects, as well as whole genome gene expression changes and gene-specific DNA methylation, in human embryonic pulmonary fibroblasts (HEL 12469) exposed to two types of carbon dots: (1) quaternized carbon dots (pCDs) with positive charge [17] and (2) carbon dots with negative charge (nCDs) [18]. We further identified mRNA targets of miRNAs found to be deregulated in our study and performed an analysis of pathways deregulated by CDs exposure.
2. Results

2.1. Physico-Chemical Properties of CDs

As pCDs have quaternized a group on the surface originating from betaine, the particles exhibited positive zeta-potential with a peak at 40 mV (Figure 1A). In contrast, the particles prepared from citric acid and urea have typically carboxylic and amidic groups on the surface, which is reflected in the strong negative zeta-potential (Figure 1A). Therefore, the tested particles were denoted as positive CDs (pCDs), or negative (CDs), respectively. The fluorescent excitation-emission maps for both of the prepared CDs are presented in Figure 1B,C. The most dominant fluorescent emission of pCDs was in the blue region of the spectra. The nCDs exhibited an excitation dependent emission, originated from the different types of nitrogen, in the core of the particles as previously reported [18]. Both particles have similar size (diameter of approx. 3 nm as detected by transmission electron microscope; hydrodynamic diameter 5–6 nm as illustrated by dynamic light scattering) and globular (Figure S1).

![Figure 1](image)

Figure 1. Zeta-potential of the prepared CDs in water at pH 7.0 (A); fluorescent excitation-emission map of pCDs (B); fluorescent excitation-emission map of nCDs (C); FT-IR spectra of pCDs and nCDs with highlighted characteristic vibration bands (D); high-resolution C 1s XPS spectrum of pCDs with survey spectrum in the inset (E); high-resolution C 1s XPS spectrum of nCDs with survey spectrum in the inset (F).

According to the Fourier transformed infrared spectroscopy results (FT-IR, Figure 1D), both of the prepared particles exhibited a strong vibration at 1600–1650 cm$^{-1}$, corresponding to C=C vibration typical for aromatic regions of the particles (sp$^2$ core of the particles). The pCDs had very dominant peaks at 2930 cm$^{-1}$ and 1450 cm$^{-1}$, characteristic for C–H stretching and bending mode reflecting the presence of CH$_3$ groups of quaternary ammonium [19]. The FT-IR spectrum of nCDs had peaked at 1105 cm$^{-1}$, a stretching mode of C–O bond. The presence of C=O bond in nCDs was reflected in an extended shoulder (1710 cm$^{-1}$) of C=C vibration. The x-ray photoelectron survey spectra (XPS) of the prepared samples (Figure 1E,F) show the presence of carbon, oxygen and nitrogen in both samples (for details, see Table S1). The chlorine in pCDs reflects the presence of a counter ion to the surface quaternary ammonium group. The high resolution C 1s XPS spectra of both samples revealed the presence of C=C, C=O/C=N, C=O and O=C=O bonds (Figure 1E,F, Table S1). According to the expected surface functional groups, the pCDs had a more dominant C-N peak. On the other hand, the nCDs had more dominant carboxylic and carbonyl groups.
2.2. Cell Viability after pCD and nCD Exposure

pCD treatment caused a decrease in cell viability (below 95% when compared with the control) at concentrations ≥ 100 μg/mL, while for nCDs, even at the highest concentration tested (500 μg/mL), the viability remained over 95% (Figure 2). Furthermore, at a concentration of 50 μg/mL, both pCD and nCD were internalized in cellular vesicles as indicated by fluorescence signal from confocal microscopy in four different layers of z plane (Figure S2). Based on these results we selected the following concentrations of CDs for mRNA, miRNA and DNA methylation experiments: 10 and 50 μg/mL, for pCD and nCD tests, respectively.

![Figure 2. Live-Dead analysis of HEL cells after 24 h treatment with various concentrations of pCDs and nCDs. The results were normalized to the control sample (100% viability). * p < 0.05; ** p < 0.01.](image)

2.3. Expression of mRNAs Induced by pCD and nCD NPs Treatment

The incubation of HEL12469 cells with pCD affected the expression of a lower number of mRNAs than those exposed to nCD (Table S2). For pCD, we observed a differential expression of 3, 61, 8 and 727 mRNAs, after incubation with 10 μg/mL for 4 h (4h10), 50 μg/mL for 4 h (4h50), 10 μg/mL for 24 h (24h10) and 50 μg/mL for 24 h (24h50), respectively (Figure 3A, Table S2). Most of these deregulated mRNAs were unique for individual exposure conditions. There were few commonly expressed mRNAs, of which only one mRNA was common for exposure to 24h10, 24h50 and 4h50 of pCD (DCBLD2, encoding discoidin, CUB and LCCL domain-containing protein 2) (Table S3A). The number of downregulated mRNAs was higher than those that were upregulated (2, 35, 7 and 432; 1, 26, 1 and 295, for downregulated and upregulated mRNAs after exposure to 4h10, 4h50, 24h10 and 24h50 pCD, respectively) (Table S2). Hierarchical clustering of top-ranked differentially expressed mRNAs in the exposed samples when compared with the controls, is shown in Figure 4. Selected significantly deregulated mRNAs with |log2FC| > 1 and adjusted p-value < 0.05 are graphically shown in volcano plots (Figure 5A–D). The differentially expressed genes include e.g., those encoding Rho GTPase activating protein 26 (ARHGAP26), tripartite motif-containing protein 16 (TRIM16L) and CCAAT/enhancer-binding protein delta (CEBPΔ) (4h10), protein sprouty homolog 4 (SPRY4), stanniocalcin-1 (STC1), prostaglandin H synthase (PTGS2), putative survival-related protein (CASZ1), and ATP-binding cassette sub-family A member 3 (ABCA3) (4h50), leukotriene B4 receptor 2 (LTB4R2), nuclear receptor coactivator 7 (NCOA7) (24h10), insulin induced gene 1 (INSIG1), transforming growth factor, β-induced (TGFBI), cell division cycle-associated protein 3 (CDCA3) and cell-division cycle protein 20 (CDC20) (24h50).
(INSIG1), transforming growth factor, β-induced (TGFBI), cell division cycle-associated protein 3 (CDCA3) and cell-division cycle protein 20 (CDC20) (24h50).

Figure 3. The distribution of common and unique mRNAs differentially expressed after CD NPs exposure; a comparison between doses and exposure times for pCD (A) and nCD (B).

Figure 4. Hierarchical clustering of top-ranked differentially expressed mRNAs in samples exposed to pCD when compared with the controls. The 20 most significantly deregulated transcripts are shown.
The incubation of HEL12469 cells with nCD resulted in the deregulation of 147, 2463, 383 and 2266 mRNAs [for 10 µg/mL for 4 h (4h10), 100 µg/mL for 4 h (4h100), 10 µg/mL for 24 h (24h10) and 100 µg/mL for 24 h (24h100), respectively (Figure 3B, Table S2)]. In contrast to pCD, for nCD we found more commonly deregulated mRNAs, of which twelve were common for all exposure conditions (Figure 3B, Table S3B). The numbers of downregulated mRNAs were as follows: 78, 912, 203 and 977 for 4h10, 4h100, 24h10 and 24h100 exposure, respectively. For upregulated mRNAs, we detected 69, 1551, 180 and 1289 differentially expressed genes after exposure to 4h10, 4h100, 24h10 and 24h100, respectively (Table S2). Hierarchical clustering of top-ranked differentially expressed genes detected in the treated samples vs. the controls for individual exposure conditions, is reported in Figure 6. Selected significantly differentially expressed mRNAs with log2FC >1 and adjusted p-value >0.05 is shown in Figure 7. The following notable deregulated transcripts were detected: ERBB receptor feedback inhibitor 1 (ERRFI1), leukemia inhibitory factor (LIF), dual specificity protein phosphatase 1 (DUSP1), interleukin 11 (IL11) (4h10, 4h100), G2 and S phase-expressed protein 1
(GTSE1), cell-division cycle protein 20 (CDC20), LBH regulator of Wnt signaling pathway (LBH) (24h10), cell division cycle-associated protein 3 (CDCA3), G2 and S phase-expressed protein 1 (GTSE1), ribonucleoside-diphosphate reductase subunit M2 (RRM2), endothelial PAS domain-containing protein 1 (EPAS1) and cyclin-dependent kinase 2 (CDK2)(24h100).

Figure 6. Hierarchical clustering of top-ranked differentially expressed mRNAs in samples exposed to nCD when compared with the controls. The 20 most significantly deregulated transcripts are shown.
Figure 7. Volcano scatter-plots showing the relationship between significance and fold change of individual mRNA transcripts expression. The horizontal dashed red line highlights the adjusted p-value of 0.05, the vertical lines denote the fold changes equal of 0.5 and 2. In each plot the 20 most significant transcripts are identified. (A)-nCD4h10, (B)-nCD4h100, (C)-nCD24h10, (D)-pCD24h100.

We further compared the differences between mRNAs affected by exposure to individual NPs. After 4 h incubation, most of the deregulated mRNAs were unique for the tested NPs however we found a total of 25 mRNAs commonly differentially expressed after exposure to both materials, regardless of their concentration. One of these mRNAs (ARHGAP26, encoding Rho GTPase activating protein 26) was common for all exposure conditions (Figure 8A, Table S3C). A dose of 10 µg/mL, that was common for both NPs, affected the differential expression of one common gene. Most of the commonly deregulated mRNAs were downregulated (19 transcripts); upregulation was observed for the differential expression of six genes. The longer incubation resulted in the deregulation of a higher number of common transcripts; 175 mRNAs differentially expressed after exposure to both NPs, regardless of concentration. Two genes were commonly differentially expressed for all tested conditions (DCBLD2, encoding discoidin, CUB and LCCL domain containing two proteins; GFRA1, encoding GDNF family receptor α 1 protein); one gene after exposure to a dose of 10 µg/mL of both materials (IGFBP3, encoding insulin-like growth factor binding protein 3) (Figure 8B, Table S3D).
Similarly to short exposure, 24 h incubation was associated with the downregulation of a greater number of mRNAs, than with the gene upregulation (118 vs. 50 mRNAs).

In agreement with the findings for deregulated mRNAs, the functional enrichment analysis revealed differences between the number of deregulated pathways after exposure to pCD and nCD. For pCD, significantly deregulated pathways were identified only after 24 h50 exposure (Table 1). These pathways were related to cell cycle and its regulation (e.g., Cell Cycle, Cell Cycle Checkpoints, G1/S Transition, M Phase) as well as cholesterol biosynthesis, which is also related to cell cycle progression.

| ID   | Source   | Deregulated Pathway          | q-Value | Deregulated Genes (N) | Genes in Pathway (N) |
|------|----------|------------------------------|---------|-----------------------|----------------------|
| 83039| KEGG     | DNA Replication              | <0.001  | 14                    | 36                   |
| 1269741| REACTOME | Cell Cycle                   | <0.001  | 106                   | 624                  |
| 1269810| REACTOME | M Phase                      | <0.001  | 48                    | 311                  |
| 1269768| REACTOME | G1/S Transition              | <0.001  | 25                    | 121                  |
| 1269772| REACTOME | G1/S-Specific Transcription  | <0.001  | 12                    | 18                   |
| 1269784| REACTOME | DNA strand elongation        | <0.001  | 17                    | 32                   |
| 1269742| REACTOME | Cell Cycle Checkpoints       | <0.001  | 29                    | 204                  |
| 1269777| REACTOME | S Phase                      | <0.001  | 29                    | 132                  |
| 1270037| REACTOME | Cholesterol biosynthesis     | <0.001  | 9                     | 24                   |

Exposure to nCD resulted in the deregulation of a higher number of pathways. The 100 µg/mL concentration applied for 4 h, affected protein translation (Eukaryotic Translation Elongation, Eukaryotic Translation Initiation, Eukaryotic Translation Termination), Gene expression, and Pathways in cancer. Similarly to pCD, the 24 h treatment with nCD was associated with processes related to cell cycle regulation, additionally possibly linked with processes of carcinogenesis for the lower dose (p53 signaling pathway), and protein expression and DNA repair for the higher dose (Table 2). The overview of deregulated pathways is graphically illustrated in Figure 9, details are provided in Figure S3.
Figure 9. The graphically illustrated overview of deregulated pathways after CD NPs exposure. (A) indicates the number of deregulated pathways, meanwhile (B) shows in which exposure conditions the selected pathways are deregulated (empty rectangles denote pCD exposure, filled rectangles denote nCD exposure).
### Table 2. Selected pathways deregulated after nCD NPs exposure.

| ID     | Source     | Deregulated Pathway                              | \(q\)-Value | Deregulated Genes (N) | Genes in Pathway (N) |
|--------|------------|--------------------------------------------------|--------------|-----------------------|----------------------|
|        | nCD 4 h 100 \(\mu\)g/mL                      |                                                     |              |                       |                      |
| 83105  | KEGG       | Pathways in cancer                              | <0.001       | 82                    | 395                  |
| 1268690| REACTOME   | Eukaryotic Translation Elongation               | <0.001       | 49                    | 98                   |
| 1268679| REACTOME   | Eukaryotic Translation Initiation               | <0.001       | 55                    | 127                  |
| 1268692| REACTOME   | Eukaryotic Translation Termination              | <0.001       | 47                    | 97                   |
| 1269649| REACTOME   | Gene Expression                                 | <0.001       | 345                   | 1844                 |
| 1268678| REACTOME   | Translation                                     | <0.001       | 68                    | 165                  |
|        | nCD 24 h 10 \(\mu\)g/mL                       |                                                     |              |                       |                      |
| 83039  | KEGG       | DNA Replication                                 | <0.001       | 8                     | 36                   |
| 83055  | KEGG       | p53 signaling pathway                           | <0.001       | 9                     | 69                   |
| 1269741| REACTOME   | Cell Cycle                                      | <0.001       | 63                    | 624                  |
| 1269810| REACTOME   | M Phase                                         | <0.001       | 26                    | 311                  |
| 1269768| REACTOME   | G1/S Transition                                 | <0.001       | 18                    | 121                  |
| 1269772| REACTOME   | G1/S-Specific Transcription                     | <0.001       | 5                     | 18                   |
| 1269784| REACTOME   | DNA strand elongiation                          | <0.001       | 11                    | 32                   |
| 1269742| REACTOME   | Cell Cycle Checkpoints                          | <0.001       | 16                    | 204                  |
| 1269777| REACTOME   | S Phase                                         | <0.001       | 21                    | 132                  |
|        | nCD 24 h 100 \(\mu\)g/mL                      |                                                     |              |                       |                      |
| 83039  | KEGG       | DNA Replication                                 | <0.001       | 24                    | 36                   |
| 1269741| REACTOME   | Cell Cycle                                      | <0.001       | 216                   | 624                  |
| 1269810| REACTOME   | M Phase                                         | <0.001       | 104                   | 311                  |
| 1269768| REACTOME   | G1/S Transition                                 | <0.001       | 49                    | 121                  |
| 1269772| REACTOME   | G1/S-Specific Transcription                     | <0.001       | 15                    | 18                   |
| 1269784| REACTOME   | DNA strand elongiation                          | <0.001       | 25                    | 32                   |
| 1269742| REACTOME   | Cell Cycle Checkpoints                          | <0.001       | 66                    | 204                  |
| 1269777| REACTOME   | S Phase                                         | <0.001       | 52                    | 132                  |
| 1268690| REACTOME   | Eukaryotic Translation Elongation               | <0.001       | 38                    | 98                   |
| 1268679| REACTOME   | Eukaryotic Translation Initiation               | <0.001       | 43                    | 127                  |
| 1268692| REACTOME   | Eukaryotic Translation Termination              | <0.001       | 36                    | 97                   |
| 1270350| REACTOME   | DNA Repair                                      | <0.001       | 80                    | 319                  |

2.4. The Expression of miRNAs Affected by Treatment with pCD and nCD NPs

The short, 4 h exposure of HEL12469 cells to a lower dose of pCD NPs, had no effect on miRNA expression. For other tested doses and exposure periods, deregulated miRNAs were found: 3, 31 and 76 miRNAs, after incubation with 4h50, 24h10 and 24h50, respectively (Figure 10A, Table S4). We observed a very small overlap of deregulated miRNAs between both exposure periods: only three molecules, regardless of concentration, were commonly expressed after exposure for 4 h and 24 h (Table S5A).

Incubation of the cells with nCD NPs affected the higher number of miRNAs when compared with pCD NPs: 25, 147, 77 and 220 miRNAs, were differentially expressed after exposure to 4h10, 4h100, 24h10 and 24h100, respectively (Figure 10B, Table S4). Although 142 miRNAs were unique, we found a total of 28 miRNA commonly deregulated for both time periods, of which 19 were common for both concentrations and exposure times. Interestingly, we observed 82 miRNAs to be commonly expressed after exposure to 100 \(\mu\)g/mL for both time periods (Table S5B).
Only two deregulated miRNA genes were detected for the treatment with the common concentration of 10 µg/mL (Figure 11B, Table S5D).

We then focused on the differences in miRNA expression induced by both the tested nanomaterials, after individual exposure periods. As expected, after the short treatment, we found no miRNAs commonly deregulated for both materials (Figure 11A, Table S5C). The longer incubation resulted in a common deregulation of a total of 20 miRNAs, of which two were common for all exposure conditions. Only two deregulated miRNA genes were detected for the treatment with the common concentration of 10 µg/mL (Figure 11B, Table S5D).

The number of differentially expressed validated miRNA targets detected in our study, out of the total number of targets identified using a database search, for miRNAs significantly deregulated after exposure to pCD and nCD NPs are reported in Table S6. In agreement with the observations described above, the number of such targets was low for pCD NPs treatment; significant results were only observed for the 24h50 exposure. In contrast, for all nCD treatment conditions, differentially expressed validated targets were identified; their numbers generally increased with the dose and time of exposure.
We further performed the functional enrichment analysis of significantly deregulated miRNAs based on experimentally validated miRNA-mRNA interactions, with the aim to identify pathways affected by exposure to pCD and nCD NPs. In general, after 24 h exposure, we observed a great overlap of deregulated pathways (Tables 3 and 4). Both CDs impacted cancer-related pathways (e.g., Colorectal cancer, Pancreatic cancer, Endometrial cancer), as well as other pathways associated with tumorigenesis (e.g., Wnt signaling pathway, Ras signaling pathway, ErbB signaling pathway), immune response-related processes (T cell receptor signaling pathway, Fc gamma R-mediated phagocytosis) and cell-extracellular matrix (ECM) interactions (Mucin type O-Glycan biosynthesis). While no significant results were found after 4 h pCD treatment, nCD caused the deregulation of pathways involved in cell-extracellular matrix (ECM) interactions (Mucin type O-Glycan biosynthesis, ECM-receptor interaction). These NPs further affected fatty acid biosynthesis and apoptosis. The overview of pathways identified based on miRNA-mRNA interactions is reported in Figure 12, details are provided in Figure S4.

Table 4. Cont.

| Pathway                                      | p-value | A   | B       |
|----------------------------------------------|---------|-----|---------|
| MAPK signaling pathway                       | 0.002   | 87  | 191     |
| ECM-receptor interaction                     | 0.002   | 72  | 61      |
| Fatty acid biosynthesis                      | <0.001  | 34  | 9       |
| T cell receptor signaling pathway            | <0.001  | 72  | 85      |
| Fc gamma R-mediated phagocytosis             | 0.024   | 77  | 66      |
| Ras signaling pathway                        | 0.036   | 70  | 66      |
| Apoptosis                                    | 0.016   | 76  | 84      |

Figure 12. Graphically illustrated overview of deregulated pathways based on miRNA-mRNA interactions after CD NPs exposure. Number (A) and identity (B) of deregulated pathways per CD, dose and exposure time (empty rectangles denote pCD exposure, filled rectangles denote nCD exposure).
Table 3. Selected pathways based on miRNA-mRNA interactions deregulated after pCD NPs exposure.

| ID    | Deregulated Pathway                       | q-Value | miRNA (N) | Genes (N) |
|-------|-------------------------------------------|---------|-----------|-----------|
|       | **pCD 24 h 10 µg/mL**                     |         |           |           |
| hsa00512 | Mucin type O-Glycan biosynthesis           | <0.001  | 5         | 11        |
| hsa05214 | Glioma                                    | 0.049   | 5         | 15        |
| hsa05210 | Colorectal cancer                         | 0.003   | 5         | 20        |
| hsa05212 | Pancreatic cancer                         | 0.013   | 5         | 19        |
| hsa05213 | Endometrial cancer                        | 0.028   | 6         | 17        |
|       | **pCD 24 h 50 µg/mL**                     |         |           |           |
| hsa00512 | Mucin type O-Glycan biosynthesis           | <0.001  | 24        | 26        |
| hsa05214 | Glioma                                    | 0.005   | 41        | 45        |
| hsa05210 | Colorectal cancer                         | <0.001  | 41        | 48        |
| hsa05212 | Pancreatic cancer                         | <0.001  | 41        | 52        |
| hsa05213 | Endometrial cancer                        | <0.001  | 41        | 42        |
| hsa04310 | Wnt signaling pathway                     | <0.001  | 44        | 99        |
| hsa04012 | ErbB signaling pathway                    | <0.001  | 41        | 66        |
| hsa05200 | Pathways in cancer                        | <0.001  | 47        | 266       |
| hsa04014 | Ras signaling pathway                     | <0.001  | 44        | 156       |
| hsa04010 | MAPK signaling pathway                    | 0.040   | 44        | 160       |
| hsa00061 | Fatty acid biosynthesis                   | <0.001  | 15        | 8         |
| hsa04660 | T cell receptor signaling pathway          | 0.024   | 41        | 71        |
| hsa04666 | Fc gamma R-mediated phagocytosis          | 0.007   | 41        | 64        |

Table 4. Selected pathways based on miRNA-mRNA interactions deregulated after nCD NPs exposure.

| ID    | Deregulated Pathway                       | q-Value | miRNA (N) | Genes (N) |
|-------|-------------------------------------------|---------|-----------|-----------|
|       | **nCD 4 h 10 µg/mL**                      |         |           |           |
| hsa00512 | Mucin type O-Glycan biosynthesis           | 0.009   | 9         | 7         |
| hsa04512 | ECM-receptor interaction                  | <0.001  | 10        | 17        |
|       | **nCD 4 h 100 µg/mL**                     |         |           |           |
| hsa00512 | Mucin type O-Glycan biosynthesis           | <0.001  | 46        | 23        |
| hsa05214 | Glioma                                    | <0.001  | 78        | 52        |
| hsa05210 | Colorectal cancer                         | 0.013   | 73        | 50        |
| hsa05212 | Pancreatic cancer                         | 0.003   | 79        | 53        |
| hsa05213 | Endometrial cancer                        | 0.022   | 72        | 42        |
| hsa04310 | Wnt signaling pathway                     | 0.003   | 89        | 108       |
| hsa04012 | ErbB signaling pathway                    | <0.001  | 86        | 73        |
| hsa05200 | Pathways in cancer                        | <0.001  | 94        | 303       |
| hsa04014 | Ras signaling pathway                     | <0.001  | 91        | 175       |
| hsa04010 | MAPK signaling pathway                    | 0.018   | 93        | 184       |
| hsa04512 | ECM-receptor interaction                  | <0.001  | 21        | 27        |
| hsa00061 | Fatty acid biosynthesis                   | <0.001  | 34        | 10        |
|       | **nCD 24 h 10 µg/mL**                     |         |           |           |
| hsa00512 | Mucin type O-Glycan biosynthesis           | <0.001  | 26        | 20        |
| hsa05214 | Glioma                                    | <0.001  | 46        | 49        |
| hsa05210 | Colorectal cancer                         | 0.001   | 40        | 46        |
| hsa05212 | Pancreatic cancer                         | <0.001  | 45        | 50        |
| hsa05213 | Endometrial cancer                        | 0.006   | 40        | 40        |
| hsa04310 | Wnt signaling pathway                     | 0.007   | 52        | 93        |
| hsa04012 | ErbB signaling pathway                    | <0.001  | 51        | 66        |
| hsa05200 | Pathways in cancer                        | <0.001  | 59        | 260       |
| hsa04014 | Ras signaling pathway                     | 0.002   | 55        | 145       |
| hsa04010 | MAPK signaling pathway                    | 0.004   | 53        | 164       |
| hsa04512 | ECM-receptor interaction                  | <0.001  | 49        | 55        |
### Table 4. Cont.

| ID     | Deregulated Pathway                        | $q$-Value | miRNA (N) | Genes (N) |
|--------|--------------------------------------------|-----------|-----------|-----------|
| hsa0512| Mucin type O-Glycan biosynthesis           | <0.001    | 51        | 23        |
| hsa0514| Glioma                                     | <0.001    | 69        | 55        |
| hsa0520| Colorectal cancer                          | <0.001    | 71        | 57        |
| hsa0521| Pancreatic cancer                          | <0.001    | 72        | 58        |
| hsa0523| Endometrial cancer                         | <0.001    | 68        | 45        |
| hsa0430| Wnt signaling pathway                      | <0.001    | 84        | 108       |
| hsa0401| ErbB signaling pathway                     | <0.001    | 80        | 80        |
| hsa0520| Pathways in cancer                         | <0.001    | 91        | 288       |
| hsa0401| Ras signaling pathway                      | <0.001    | 87        | 171       |
| hsa0401| MAPK signaling pathway                     | 0.002     | 87        | 191       |
| hsa0451| ECM-receptor interaction                   | 0.002     | 72        | 61        |
| hsa0061| Fatty acid biosynthesis                    | <0.001    | 34        | 9         |
| hsa0460| T cell receptor signaling pathway          | <0.001    | 72        | 85        |
| hsa0466| Fc gamma R-mediated phagocytosis           | 0.024     | 77        | 66        |
| hsa0420| Apoptosis                                  | 0.036     | 70        | 66        |
| hsa0468| TNF signaling pathway                      | 0.016     | 76        | 84        |

#### 2.5. DNA Methylation Changes after Treatment with pCD and nCD NPs

An investigation of gene specific DNA methylation changes was performed with the aim to identify differentially methylated CpG sites and regions. However, we did not find any significant results for either exposure condition, suggesting that the tested NPs have any effect on DNA methylation under the selected treatment conditions (NPs concentration and/or time of exposure) (data not shown).

#### 3. Discussion

Our results showed, for the first time in human cells, that treatment with CDs gave rise to the deregulation of mRNA and miRNA gene expression and that the resulting deregulated pathways were shared for the different conditions we tested. Nevertheless, we saw a trend for a dose/exposure-time response curve, with higher doses and longer exposure time, showing more deregulation. Furthermore, we found that the CD’s surface charge is important, with the positively charged pCD giving rise to less deregulation than the negatively charged nCD nanoparticles. In terms of epigenetic changes, we saw a deregulation of miRNA pathways, but no DNA methylation changes. For our experiments we used human embryonic lung fibroblasts as a model system. Although fibroblasts do not represent a primary target for particles entering the pulmonary system, they become exposed in damaged areas of the lungs, e.g., after exposure to various pollutants, including nanoparticles [20,21]. In such tissues, fibroblasts proliferate and consequently play a major role in the response to external stimuli. Additionally, due to their small size, CDs could easily penetrate through the epithelial cells and affect other cells, including fibroblasts, even if the lung epithelium is intact [22].

Carbon dots have potential to be used as a labeling agent not only in regenerative medicine [23], but also for targeted imaging and gene delivery in cancer therapy, including lung tumors [24,25]. For such treatments, it is paramount that healthy tissues are not negatively impacted by the introduction of foreign particles. The studies analyzing the negative biological effects of CDs have usually focused on the detection of cytotoxicity, cell cycle alterations or ROS production. The authors mostly noted the very low cell-specific and surface passivation-dependent toxicity of these NMs (e.g., [4–9]). However, in a study performed in a plant model *Arabidopsis thaliana* (L.), the negative impacts of CDs exposure on root elongation were observed for higher tested doses, suggesting phytotoxicity in this organism [13]. In that study, a comprehensive genomics analysis using next generation sequencing (NGS) was conducted. The expression of more than 600 genes in the roots and shoots were upregulated, including those involved in cellular response to phosphate starvation, stimulus response, and UDP-glycosyltransferase
activity. On the contrary, the expression of more than 500 genes, mainly those responsible for chloroplast functions and structure, was downregulated. However, no comparable assessment of CDs effects on genomics parameters was conducted in animal systems.

To date, very limited information on the potential toxicity of pCD and nCD used in this study is available. In mouse fibroblasts NIH/3T3 exposed to pCD, the viability detected using the MTT assay was not affected after treatment with concentrations relevant for cell imaging [15]. Malina et al. [16] exposed human mesenchymal stromal cells to pCD. By the detection of ROS generation, analyses of cell viability, cell cycle changes, and DNA fragmentation by comet assay, they discovered that these carbon nanoparticles are biocompatible, even at a very high dose (400 µg/mL) and did not cause a negative effect on the behavior or native function of the cells at a dose of 100 µg/mL. Thus, in these cell models pCD may represent a suitable material for biomedical applications. However, no such evidence was reported for other cell types. Moreover, to the best of our knowledge, no toxicological studies were performed with nCD.

In this study, treatment with a positively charged pCD resulted in the reduction of cell viability, already detectable at a concentration of 100 µg/mL. In contrast, exposure to negatively charged nCD had no measurable adverse impact on viability, even at a dose of 500 µg/mL. Similar data showing surface charge-dependent toxicity were obtained by Havrdova et al. [7] for another group of CDs. In agreement with our cell viability data, the changes of mRNA and miRNA expression evaluated as the number of deregulated transcripts were more pronounced in samples treated with nCD, than in those exposed to pCD. This result was obtained already at a dose of 10 µg/mL when no reduction of cell viability was detected. We speculate that pCD had inhibitory effects on gene expression even at the lower tested concentration that was not detectable by the live-dead analysis. Such response may have been manifested by lower numbers of deregulated genes induced by pCD.

For mRNA expression, we observed some notable unique differentially expressed molecules for individual exposure periods and doses of CDs. Although these changes suggest the possible direction of cellular impacts of the tested CDs, it should be noted that the biological significance of modulations based on the deregulation of single genes is limited and that pathway analyses provide better overall demonstration of impacts of the investigated NMs on the organism.

Thus, after 4h10 exposure to pCD, the expression of ARHGAP26 encoding a protein participating in endocytosis and associated with cancer was upregulated, and TRIM16L involved in cell growth, differentiation and pathogenesis, as well as CEBPD encoding the protein involved in immune and inflammatory responses were downregulated, suggesting the potential impacts of these CDs on immunity, surfactant production [26] and lung carcinogenesis [27]. The effects modulated by the 4h50 exposure to pCD were mostly comparable. We observed a reduced expression of STC1, that encodes stanniocalcin 1, a protein reported to functionally participate in the development of some cancers, including lung cancer [28]. The expression of SPRY4 that has been shown to inhibit cell growth and migration in non-small lung cancer [23] was also downregulated. The upregulation of ABCA3, encoding multi-membrane spanning protein, that plays a critical role in pulmonary surfactant homeostasis [24] was detected. Finally, the potential anti-inflammatory role of pCD exposure was suggested by a decreased expression of PTGS2.

After 24 h of treatment, pCD reduced the expression of genes related to inflammation (CCL2, LTB4R2). In addition, the expression of TGFBI encoding a protein that plays a role in cell-collagen interactions was upregulated. The loss of expression of this gene was reported in several cancers, including lung cancer [25]. The expression of genes encoding cell division cycle-associated proteins (CDCA3, CDC20) was downregulated. The modulation of their expression was associated with lung cancer [29,30]. Finally, the genes encoding proteins involved in mitochondria functions and oxidative phosphorylation (MT-ATP6, MT-ATP8, MT-CO2, MT-CO3 or MT-CYB), were affected by these CDs. Overall, the data indicate the potential inhibitory role of pCD on cell cycle progression, as well as an association with oxidative stress, but also the possible induction of apoptotic response [31].
Four hours of exposure to nCD downregulated the expression of: *ERRFI1* whose protein product regulates DNA damage response and promotes DNA repair [32]; *LIF* that is involved e.g., in inflammatory response [33]; and *DUSP1* that plays a role in the response to stress and negatively regulates cellular proliferation [34]. We further detected the deregulation of genes encoding proteins interacting with p53 tumor suppressor (*TP53BP1, MDM2*) or cyclins and other cell cycle regulation genes (e.g., *CCNB1, CCNF, CCNI, CCNK, CCNL1, CCNT2* or genes encoding cyclin-dependent kinases). Thus, 4 h exposure to nCD is potentially linked with the disturbance of DNA damage response and carcinogenesis [35].

The expression of *CDC20* was downregulated by the 24h10 treatment with nCD. These NPs further reduced the expression of *GTSE1*, whose protein product binds p53 and thus blocks apoptosis. Its expression was observed in radiation-induced lung fibrosis [36]. The exposure to 24h50 nCD was associated with the downregulation of *GTSE1* as well as *CDCA3* and expression. Similar results were observed for *RRM2* and *CDK2*. The protein encoded by *RRM2* is linked with the synthesis of deoxyribonucleotides from ribonucleotides, and its expression is associated with poor prognosis in non-small cell lung cancer patients [37]. *CDK2*, an important regulator of cell cycle, was consistently found to be overexpressed in human cancers, including lung cancer [38]. *DDB2* encoding DNA damage-response protein, genes encoding subunits of mitochondrial ATP synthase, collagen, as well as oncogenes and tumor suppressor genes, including *TP53* were also modulated by nCD exposure. Thus, apart from the possible impacts on oxidative stress and apoptosis described above, these CDs might affect collagen deposition and therefore contribute to lung fibrosis [39]. The link of nCD exposure with tumorigenesis is not consistent and final conclusions cannot be drawn based on the obtained data.

As already suggested, although the numbers of differentially expressed genes and pathways differed for the tested CDs and few genes were commonly expressed, the altered biological functions and processes partly overlapped. This was further confirmed by the analysis of deregulated pathways based on mRNA expression that showed the impact of both CDs on cell cycle regulation. Therefore, our data indicate that both tested CDs share similar mechanisms by which they affect mRNA expression, although the particular doses, exposure times and impacted processes may differ.

To assess the impact of CDs exposure on epigenetic parameters, we focused on miRNA and DNA methylation alterations. While miRNA expression changes may occur during a short time-span, DNA methylation is a slower process with long-lasting consequences. Thus, we expected differences in behavior of these epigenetic markers. As already described, for differential miRNA expression analysis, we detected changes comparable with those found for mRNA. This observation indicates that this parameter readily responds to the presence of CDs in the treated cells. The analysis of pathways related to miRNA expression changes showed a very similar pattern for both CDs. Although the number of pathways deregulated by pCD exposure was substantially lower than that affected by nCD, both nanomaterials were involved in the deregulation of various tumorigenesis-related pathways, extracellular matrix interactions and immune response. In addition, exposure to nCD affected apoptosis. The analysis of gene-specific DNA methylation did not show an effect of either type of CDs on this epigenetic parameter. Although this is the first study in which such analysis was performed, we believe that short exposure times are responsible for the negative observations. In a recent study, persistent global DNA methylation changes were found in zebrafish exposed to various nano-graphene quantum dots for 7 days [40]. Although the experimental model and the method of DNA methylation detection were different than in our study, the longer exposure period was most likely the reason for the positive results observed by these authors. Our results suggest that, from the long-term perspective, short-term exposures are not deleterious for the organism. The changes detected on an mRNA level are probably limited to a short period of time. Thus, to elucidate the potential impact of pCDs and nCDs on gene-specific DNA methylation changes in HEL 12469 cells, a different time exposure scheme involving prolonged exposure periods will be necessary.

In summary, we described the whole genome gene expression changes in human embryonic lung fibroblasts after exposure to two types of carbon dots—positively charged pCD and negatively charged
nCD. Despite differential cellular response, most likely related to distinct surface charge, manifested by the deregulation of a greater number of mRNAs, miRNAs and associated pathways after exposure to nCD, both types of CDs seem to have similar biological impacts. These are associated with the potential changes of immune response and cell cycle-related processes. Nevertheless, pCD, especially at low doses, appear to show a more learned profile. However, our data should be interpreted with caution, as they mostly reflect processes on the transcription level without corresponding confirmation of the expression of translated proteins. Consequently, for future biomedical applications of these CDs more tests, preferentially in animal models, should be carried out. These experiments should include not only genomic analyses, but also the detection of relevant phenotypic markers.

4. Materials and Methods

4.1. Carbon Dots and Their Characterization

The materials were obtained according to our previous protocols [17,18]. The positive charged carbon dots were prepared by solid-state carbonization of betaine hydrochloride and tris (hydroxymethyl) aminomethane (TRIS). The negative charged CDs were produced by the solvo-thermal method; the autoclave decomposition of citric acid and urea in dimethylformamide (DMF). The only modification was in the preparation of nCDs, mainly in the purification protocol. The prepared particles were not separated by ionex-chromatography as previously reported, but repeatedly washed with water over a 3 kDa ultrafiltration membrane (Millipore ultrafiltration tube). The unreacted precursor and DMF passed through the filter. The purified nCDs stayed in the ultrafiltration inset. The particles were subsequently freeze-dried and dissolved, before use at required concentrations.

Fluorescence spectroscopy was performed on a FLS980 fluorescence spectrometer (Edinburgh Instruments, Livingston, UK) equipped with a R928P photomultiplier (Hamamatsu, Hamamatsu City, Japan) in a thermoelectrically cooled housing, with a 450 W xenon arc lamp as the excitation source for steady-state spectra and an EPL-375 picosecond pulsed diode laser (λem = 372 nm; Edinburgh Instruments). Zeta potential (ξ potential) of CDs was measured using Zetasizer NanoZS (Malvern, Worcestershire, UK).

FTIR spectra were measured using Nicolet i55 FTIR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped with the Smart Orbit ZnSe ATR technique. Survey and high-resolution C1s XPS spectra were assessed by X-ray photoelectron spectroscopy (XPS) and carried out with a PHI VersaProbeII (Physical Electronics, Chanhassen, MN, USA) spectrometer using an A1 Kalfa source (15 kV, 50 W). The obtained data were evaluated with the MultiPak (ULvac – PHI, Inc., Kanagawa, Japan) software package and are referred to C 1s peak at 284.80 eV.

Size and shape of the CDs were characterized by transmission electron microscopy (TEM, JEOL 2100 operating at 160 kV, JEOL, Akişima, Tokyo, Japan). Zeta potential (ξ potential) and DLS (dynamic light scattering) of CDs were measured using Zetasizer NanoZS. The confirmation of pCD and nCD uptake by the cells was performed using a confocal microscope (Olympus, Tokyo, Japan) equipped with laser with 488 nm excitation and detector for emission in the region of 520 to 560 nm. The measurement was done by 60× objective with 1.5× zoom. HEL12469 cells were treated with 50 µg/mL of pCDs and nCDs for 24 h, then the sample was washed with PBS. The measurement was conducted in PBS.

4.2. Cell Culture Treatment and Viability Assay

HEL 12469 cells were grown at 37 ºC in a humidified atmosphere containing 5% CO₂ in Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum, 2 mM glutamine, 1% non-essential amino acids and 0.2% sodium bicarbonate. After reaching 70–80% confluence, the medium was replaced with a complete fresh medium. Prior to exposure, the medium was removed; the cells were then washed and treated with freshly prepared dilutions of only CDs or media (negative controls; NC). Each CD was tested in triplicate.
Cell viability was evaluated using a live/dead analysis. The cells were seeded in 96-well plates (10^4 cells/well) and cultivated overnight in a culture medium. The cells were then treated with various concentrations (10–500 µg/mL) of pCDs and nCDs. After 24 h, the supernatant was collected and the cells were washed with a phosphate-buffer solution (PBS, 0.1 M, pH 7.4), detached with trypsin (0.25% in ethylenediaminetetraacetic acid (EDTA), Sigma-Aldrich, St. Louis, MO, USA) and resuspended in 150 µL of medium. Every solution added to the cells was collected so that every cell of the sample could be analyzed and not removed during the preparation. The cells were incubated with propidium iodide (PI) (final concentration 10 µg/mL) and calcein-AM (final concentration 50 µM) for 30 min in the dark. The fluorescence signal was then measured on a flow cytometer BD FACSVerse (BD Biosciences, San Jose, CA, USA) using red and green channels (red: ex. 488/em. 700 nm, green: ex. 488/em. 527 nm). The dead cells gave a strong red signal, as PI revealed cells that had lost membrane integrity; whereas the live cells generated a green signal from highly fluorescent calcein, which was catalyzed from non-fluorescent calcein-AM by active intracellular esterases. Mean ± standard deviation (SD) was calculated from the independent experiments. Student t-test was performed using Statistica software (TIBCO, Palo Alto, CA, USA, 2018). Any difference was considered significant and highly significant at \( p \leq 0.05 \) and \( p \leq 0.01 \), respectively. Two concentrations were selected for gene expression and DNA methylation analyses. Due to toxicity, pCDs were tested at a maximum concentration of 50 µg/mL.

4.3. DNA, RNA, and miRNA Extraction

The total RNA and DNA was extracted using AllPrep DNA/RNA/miRNA Universal Kit (Qiagen Manchester Ltd., Manchester, UK). The extraction protocol followed the manufacturers’ instructions with some modifications (purification and precipitation with sodium acetate/ethanol). The concentration of nucleic acids was determined by Nanodrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA); RNA integrity number (RIN) was assessed by Agilent Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA) with RNA 6000 Nano kit (Agilent Technologies Inc., Santa Clara, CA, USA). RIN values were >9.0 in all samples.

4.4. Whole Genome Transcriptome Analysis by Next Generation Sequencing

RNA samples (concentration >210 ng/µL, RNA integrity number >9.0) were used for RNA libraries preparation using [(Poly(A)RNA Selection, Lexogen Sense Total RNA-Seq Library Prep Kit (Lexogen GmbH, Vienna, Austria)]. For sequencing, NextSeq®500/550 High Output Kit v2 (75 cycle) and NextSeq 500/550 system (Illumina, Inc., San Diego, CA, USA) were used. The reactions were performed according to the manufacturers’ recommendations.

4.5. miRNA Expression Analysis

Small RNA libraries were prepared from 150 ng of total RNA, essentially using Qiaseq miRNA library kit (Qiagen Manchester Ltd., Manchester, UK) as previously described [41]. The kit not only allows the detection of miRNAs, but also other small RNAs, including piRNAs. In our data, most of the results consisted of deregulated miRNAs, with a minor proportion of piRNAs. Thus, the “miRNA expression” reported here, denotes an expression of both miRNAs and piRNAs. Small RNA libraries were validated on a Fragment Analyzer (Agilent Technologies Inc., Santa Clara, CA, USA) with a high sensitivity NGS kit. The sequencing of sRNA libraries was performed on MiSeq system (Illumina, Inc., San Diego, CA, USA) using MiSeq Reagent Kit V3 (Illumina, Inc., San Diego, CA, USA).

4.6. Gene Specific DNA Methylation Analysis

Infinium MethylationEPIC BeadChips (Illumina, Inc., San Diego, CA, USA), allowing the interrogation of more than 850,000 CpG loci, dispersed through the whole human genome were used. A total of 500 ng DNA was treated overnight with sodium bisulfite using Zymo EZ DNA Methylation™ Kit (Zymo Research, Irvine, CA, USA) for the conversion of unmethylated cytosines
to uracils, while methylated cytosines remain unchanged. Bisulfite-converted DNA was processed according to the manufacturer’s protocol including the enzymatic fragmentation, precipitation, resuspension and overnight hybridization, followed by washing and BeadChip staining. All chips were scanned by iScan System (Illumina, Inc., San Diego, CA, USA). The methylation status at each CpG site was estimated by measuring the intensity of the pair of methylated and unmethylated probes.

4.7. Data Analysis

An NGI-RNAseq pipeline (https://github.com/SciLifeLab/NGI-RNAseq) was used for RNA sequencing data. It pre-processed raw data from FastQ inputs (FastQC, Trim Galore!), aligned the reads (HiSAT2) using reference genome Homo sapiens assembly GRCh37 (hg19), generated gene counts (featureCounts) and performed extensive quality-control on the results (RSeQC, dupRadar, Preseq, edgeR, MultiQC). DESeq2 with default parameter settings was applied to normalize read counts and to identify the differences in gene expression between sample groups. A functional enrichment analysis of differential gene expression data was performed by ToppFun tool, using the feature “Pathway” [42].

Differential miRNA expression count data were generated by QIAseq miRNA Quantification, and the UMI counts were taken to compensate for sequencing bias. The DESeq2-package was used to test for differential expression by the application of negative binomial generalized linear models. A \( p < 0.02 \) was used as the cut-off for statistically significant deregulated miRNAs between sample groups. Heatmaps were used to visualize the magnitude of expression in particular samples. In each experiment, the 20 most significant transcripts reported by DESeq2 were shown. The color corresponds to z-score reached for DESeq2 normalized read count values, i.e., each field visualizes the number of standard deviations by which the normalized read count is above or below the mean value observed for the given transcript in the given experiment (6 samples). Heatmap.2 function from gplots R package was employed for heatmaps generation. The relationship between significance and fold change reported by DESeq2 was shown using volcano scatterplots. All the transcripts (each represented by a single point) were plotted to show the overall distribution. The ggplot2 package was used to generate the plot.

The mRNA-miRNA correlation analysis was performed with the R package miRComb [43]. First, the sets of differentially expressed mRNAs and miRNAs were identified (the detection thresholds were adjusted \( pval < 0.01, FC > 1.5 \) and adjusted \( pval < 0.1 \), for mRNA and miRNA expression, respectively; the detection method was DESeq2). Correlations between all the mRNA and miRNA candidate pairs were then calculated as previously described [41].

The differential methylation analysis was carried out with the Bioconductor workflow recommended in [44]. In particular, differential methylation was detected with limma package and its empirical Bayes method, suitable for experiments where the number of arrays is small. The minfi package was used for the preprocessing, filtering and quality control, of raw methylation data. Stratified quantile normalization implemented in minfi, was also employed. The DMRcate package eventually served to extract the most differentially methylated regions.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/1422-0067/21/13/4763/s1:
Figure S1. TEM images and DLS measurement of hydrodynamic diameters of pCD and nCD. Figure S2. A confocal microscopy image of HEL12469 cells treated with 50 \( \mu \)g/mL of pCD and nCD. Figure S3. Detailed graphical overview of pathways deregulated after pCD and nCD exposure. Figure S4. Detailed graphical overview of pathways deregulated after pCD and nCD exposure identified based on miRNA-miRNA interactions. Table S1. Elemental composition of pCDs and nCDs according to the XPS analysis with deconvoluted C 1s high resolution spectra. Table S2. Lists of differentially expressed mRNA transcripts after 4 h and 24 h of exposure to pCD and nCD. The numbers of differentially expressed mRNAs for individual exposure periods are also shown. Table S3A. Common and unique deregulated mRNA transcripts after 4 h and 24 h of exposure to pCD. Table S3B. Common and unique deregulated mRNA transcripts after 4 h and 24 h of exposure to nCD. Table S3C. Common and unique deregulated mRNA transcripts after 4 h of exposure to pCD and nCD. Table S3D. Common and unique deregulated mRNA transcripts after 24 h of exposure to pCD and nCD. The numbers of differentially expressed miRNAs for individual exposure periods are also shown. Table S5A. Common and unique deregulated miRNA transcripts after 4 h and 24 h of exposure to pCD. Table S5B. Common and unique deregulated miRNA transcripts after 4 h and 24 h of exposure to pCD and nCD.
after 4 h and 24 h of exposure to nCD. Table S5C. Common and unique deregulated miRNA transcripts after 4 h of exposure to pCD and nCD. Table S5D. Common and unique deregulated miRNA transcripts after 24 h of exposure to pCD and nCD. Table S6. Numbers of detected differentially expressed validated targets and a total number of validated targets based on a database search for miRNAs significantly deregulated after exposure to pCD and nCD for individual exposure conditions.

**Author Contributions:** Conceptualization: P.R.J., J.T.; Methodology: K.V., J.K., K.P.; Software: J.K.; Formal analysis: J.K.; Investigation: K.V., T.Z., K.H., I.C., A.A., K.P., T.M., J.B.; Data curation: J.K.; Writing—original draft preparation: M.S., P.R.J.; Writing—review and editing: M.S., K.V., T.Z., K.H., A.A., J.K., A.R., K.P., T.M., J.T., P.R.J.; Visualization: M.S.; Supervision: P.R.J.; Project administration: P.R.J.; Funding acquisition: J.T., P.R.J.

All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Ministry of Education, Youth and Sports of the Czech Republic (LO1508, LM2015073), the ERDF/ESF “Nano4Future” (No. CZ.02.1.01/0.0/0.0/16_019/0000754), and by the Operational Program Prague–Competitiveness (CZ.2.16/1.00/0.0/16_019/0000754). The authors also gratefully acknowledge the support by Student Projects IGA CZ.02.1.01/0.0/0.0/16_019/0000754.

**Acknowledgments:** Avidan Neumann is acknowledged for his critical comments of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Xu, X.; Ray, R.; Gu, Y.; Ploehn, H.; Gearheart, L.; Raker, K.; Scrivens, W. Electrophoretic analysis and purification of fluorescent single-walled carbon nanotube fragments. *J. Am. Chem. Soc.* 2004, 126, 12736–12737. [CrossRef] [PubMed]

2. Duran, N.; Simoes, M.B.; de Moraes, A.C.M.; Favaro, W.J.; Seabra, A.B. Nanobiotechnology of Carbon Dots: A Review. *J. Biomed. Nanotechnol.* 2016, 12, 1323–1347. [CrossRef] [PubMed]

3. Zhao, F.; Zhao, Y.; Liu, Y.; Chang, X.; Chen, C.; Zhao, Y. Cellular Uptake, Intracellular Trafficking, and Cytotoxicity of Nanomaterials. *Small* 2011, 7, 1322–1337. [CrossRef] [PubMed]

4. Tao, H.; Yang, K.; Ma, Z.; Wán, J.; Zhang, Y.; Kang, Z.; Liu, Z. In Vivo NIR Fluorescence Imaging, Biodistribution, and Toxicology of Photoluminescent Carbon Dots Produced from Carbon Nanotubes and Graphite. *Small* 2012, 8, 281–290. [CrossRef] [PubMed]

5. Yang, S.-T.; Wang, X.; Wang, H.; Lu, F.; Luo, P.G.; Cao, L.; Meziani, M.J.; Liu, J.-H.; Liu, Y.; Chen, M.; et al. Carbon Dots as Nontoxic and High-Performance Fluorescence Imaging Agents. *J. Phys. Chem.* 2009, 113, 18110–18114. [CrossRef] [PubMed]

6. Wang, Y.; Anilkumar, P.; Cao, L.; Liu, J.-H.; Luo, P.G.; Tackett, K.N., II; Sahu, S.; Wang, P.; Wang, X.; Sun, Y.P. Carbon dots of different composition and surface functionalization: Cytotoxicity issues relevant to fluorescence cell imaging. *Exp. Biol. Med.* 2011, 236, 1231–1238. [CrossRef] [PubMed]

7. Havrdova, M.; Hola, K.; Skopalik, J.; Tomankova, K.; Martin, P.A.; Cepe, K.; Polakova, K.; Tucek, J.; Bourlinos, A.B.; Zboril, R. Toxicity of carbon dots—Effect of surface functionalization on the cell viability, reactive oxygen species generation and cell cycle. *Carbon* 2016, 99, 238–248. [CrossRef]

8. Hsu, P.-C.; Chen, P.-C.; Ou, C.-M.; Chang, H.-Y.; Chang, H.-T. Extremely high inhibition activity of photoluminescent carbon nanodots toward cancer cells. *J. Mater. Chem. B* 2013, 1, 1774–1781. [CrossRef]

9. Li, C.-L.; Ou, C.-M.; Huang, C.-C.; Wu, W.-C.; Chen, Y.-P.; Lin, T.-E.; Ho, L.-C.; Wang, C.-W.; Shih, C.-C.; Zhou, H.-C.; et al. Carbon dots prepared from ginger exhibiting efficient inhibition of human hepatocellular carcinoma cells. *J. Mater. Chem. B* 2014, 2, 4564–4571. [CrossRef]

10. Das, B.; Pal, P.; Dadhich, P.; Dutta, J.; Dhara, S. In Vivo Cell Tracking, Reactive Oxygen Species Scavenging, and Antioxidative Gene Down Regulation by Long-Term Exposure of Biomass-Derived Carbon Dots. *ACS Biomater-Sci. Eng.* 2019, 5, 346–356. [CrossRef]

11. Li, M.; Gu, M.-M.; Tian, X.; Xiao, B.-B.; Lu, S.; Zhu, W.; Yu, L.; Shang, Z.-F. Hydroxylated-Graphene Quantum Dots Induce DNA Damage and Disrupt Microtubule Structure in Human Esophageal Epithelial Cells. *Toxicol. Sci.* 2018, 164, 339–352. [CrossRef] [PubMed]

12. Sharma, A.; Panwar, V.; Chopra, V.; Thomas, J.; Kaushik, S.; Ghosh, D. Interaction of Carbon Dots with Endothelial Cells: Implications for Biomedical Applications. *ACS Appl. Nano Mater.* 2019, 2, 5483–5491. [CrossRef]
13. Chen, J.; Liu, B.; Yang, Z.; Qu, J.; Xun, H.; Dou, R.; Gao, X.; Wang, L. Phenotypic, transcriptional, physiological and metabolic responses to carbon nanodot exposure in Arabidopsis thaliana (L.). Environ. Sci. Nano 2018, 5, 2672–2685. [CrossRef]

14. Maiti, S.; Das, K.; Das, P.K. Label-free fluorimetric detection of histone using quaternized carbon dot-DNA nanobiobiody. Chem. Commun. 2013, 49, 8851–8853. [CrossRef]

15. Datta, K.K.R.; Kozak, O.; Ranc, V.; Havrdova, M.; Bourlinos, A.B.; Safarova, K.; Hola, K.; Tomankova, K.; Zoppellaro, G.; Otyepka, M.; et al. Quaternized carbon dot-modified graphene oxide for selective cell labelling—Controlled nucleus and cytoplasm imaging. Chem. Commun. 2014, 50, 10782–10785. [CrossRef]

16. Malina, T.; Polakova, K.; Skopalik, J.; Milotova, V.; Hola, K.; Havrdova, M.; Tomankova, K.B.; Cmiel, V.; Malina, T.; Polakova, K.; Skopalik, J.; Milotova, V.; Hola, K.; Havrdova, M.; Tomankova, K.B.; Cmiel, V.; Datta, K.K.R.; Kozak, O.; Ranc, V.; Havrdova, M.; Bourlinos, A.B.; Safarova, K.; Hola, K.; Tomankova, K.; Zoppellaro, G.; Otyepka, M.; et al. Quaternized carbon dot-modified graphene oxide for selective cell labelling—Controlled nucleus and cytoplasm imaging. Chem. Commun. 2014, 50, 10782–10785. [CrossRef]

17. Bourlinos, A.B.; Zboril, R.; Petr, J.; Bakandritsos, A.; Krysmann, M.; Giannelis, E.P. Luminescent Surface Quaternized Carbon Dots. Chem. Mater. 2012, 24, 6–8. [CrossRef]

18. Hola, K.; Sudolska, M.; Kalytchuk, S.; Nachtigallova, D.; Rogach, A.L.; Otyepka, M.; Zboril, R. Graphitic Nitrogen Triggers Red Fluorescence in Carbon Dots. ACS Nano 2017, 11, 12402–12410. [CrossRef]

19. Lin-Vien, D.; Colthup, N.B.; Fateley, W.G.; Grasselli, J.G. The Handbook of Infrared and Raman Characteristic Frequencies of Organic Molecules; Elsevier: Amsterdam, The Netherlands, 1991; p. 503.

20. Alley, D.F.; Langley-Turnbaugh, S.; Gordon, N.R.; Wise, J.P.; Van Eps, G.; Jalbert, A. The effect of PM10 on human lung fibroblasts. Toxicol. Ind. Health 2009, 25, 111–120. [CrossRef]

21. Li, Y.; Wang, P.; Hu, C.; Wang, K.; Chang, Q.; Liu, L.; Han, Z.; Shao, Y.; Zhai, Y.; Zuo, Z.; et al. Protein corona of airborne nanoscale PM2.5 induces aberrant proliferation of human lung fibroblasts based on a 3D organotypic culture. Sci. Rep. 2017, 8, 1939. [CrossRef]

22. Durantie, E.; Barosova, H.; Drasler, B.; Rodriguez-Lorenzo, L.; Urban, D.A.; Otyepka, M.; Zboril, R. Graphitic Nitrogen Triggers Red Fluorescence in Carbon Dots. ACS Nano 2017, 11, 12402–12410. [CrossRef]

23. Tennis, M.A.; Van Scoyk, M.M.; Freeman, S.V.; Vandervest, K.M.; Nemenoff, R.A.; Winn, R.A. Sprouty-4 Inhibits Transformed Cell Growth, Migration and Invasion, and Epithelial-Mesenchymal Transition, and Is Regulated by Wnt7A through PPAR in Non-Small Cell Lung Cancer. Mol. Cancer Res. 2010, 8, 833–843. [CrossRef][PubMed]

24. Beers, M.F.; Mulugeta, S. The biology of the ABCA3 lipid transporter in lung health and disease. Cell Tissue Res. 2017, 367, 481–493. [CrossRef]

25. Irigoyen, M.; Pajares, M.J.; Agorreta, J.; Ponz-Sarvisé, M.; Salvo, E.; Lozano, M.D.; Pio, R.; Gil-Bazo, L.; Rouzaut, A. TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol. Cancer 2010, 9, 130. [CrossRef]

26. Ballard, P.L.; Lee, J.W.; Fang, X.; Chapin, C.; Allen, L.; Segal, M.R.; Fischer, H.; Illek, B.; Gonzales, L.W.; Kolla, V.; et al. Regulated gene expression in cultured type II cells of adult human lung. Am. J. Physiol-Lung. Cell Mol. Physiol. 2010, 299, L36–L50. [CrossRef][PubMed]

27. Nie, J.-H.; Chen, Z.-H.; Shao, C.-L.; Pei, W.-W.; Zhang, J.; Zhang, S.-Y.; Jiao, Y.; Tong, J. Analysis of the miRNA-mRNA networks in malignant transformation BEAS-2B cells induced by alpha-particles. J. Toxicol. Environ. Health A 2016, 79, 427–435. [CrossRef]

28. Du, Y.-Z.; Gu, X.-H.; Cheng, S.-F.; Li, L.; Liu, H.; Hu, L.-P.; Gao, F. The oncogenic role of stanniocalcin 1 in lung adenocarcinoma: A promising serum candidate biomarker for tracking lung adenocarcinoma progression. Tumour Biol. 2016, 37, 5633–5644. [CrossRef]

29. Adams, M.N.; Burgess, J.T.; He, Y.; Gately, K.; Snell, C.; Zhang, S.-D.; Hooper, J.D.; Richard, D.J.; O’Byrne, K.J. Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer. J. Thorac. Oncol. 2017, 12, 1071–1084. [CrossRef]

30. Zhang, M.-Y.; Liu, X.-X.; Li, H.; Li, R.; Liu, X.; Qu, Y.-Q. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis. Int. J. Med. Sci. 2018, 15, 1676–1685. [CrossRef]

31. Chen, L.; Wu, L.-Y.; Yang, W.-X. Nanoparticles induce apoptosis via mediating diverse cellular pathways. Nanomedicine 2018, 13, 2939–2955. [CrossRef]
32. Li, C.; Park, S.; Zhang, X.; Eisenberg, L.M.; Zhao, H.; Darzynkiewicz, Z.; Xu, D. Nuclear Gene 33/Mig6 regulates the DNA damage response through an ATM serine/threonine kinase-dependent mechanism. *J. Biol. Chem.* 2017, 292, 16746–16759. [CrossRef] [PubMed]

33. Knight, D. Epithelium-fibroblast interactions in response to airway inflammation. *Immunol. Cell Biol.* 2001, 79, 160–164. [CrossRef] [PubMed]

34. Lei, Y.-Y.; Wang, W.-J.; Mei, J.-H.; Wang, C.-L. Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors. *Asian Pac. J. Cancer Prev.* 2014, 15, 8539–8548. [CrossRef] [PubMed]

35. Eymin, B.; Gazzeri, S. Role of cell cycle regulators in lung carcinogenesis. *Cell Adh. Migr.* 2010, 4, 114–123. [CrossRef]

36. Jin, H.; Kang, G.-Y.; Jeon, S.; Kim, J.-M.; Park, Y.N.; Cho, J.; Lee, Y.-S. Identification of molecular signatures involved in radiation-induced lung fibrosis. *J. Mol. Med.* 2019, 97, 37–47. [CrossRef]

37. Zhao, H.; Zhang, H.; Du, Y.; Gu, X. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. *Tumour Biol.* 2014, 35, 12679–12688. [CrossRef]

38. Mok, M.T.; Zhou, J.; Tang, W.; Zeng, X.; Oliver, A.W.; Ward, S.E.; Cheng, A.S. CCRK is a novel signalling hub exploitable in cancer immunotherapy. *Pharmacol. Therapeut.* 2018, 186, 138–151. [CrossRef]

39. Ko, J.-W.; Shin, N.-R.; Park, J.-W.; Park, S.-H.; Lee, I.-C.; Kim, J.-S.; Kim, J.-C.; Ahn, K.-S.; Shin, I.-S. Copper oxide nanoparticles induce collagen deposition via TGF-beta1/Smad3 signaling in human airway epithelial cells. *Nanotoxicology* 2018, 12, 239–250. [CrossRef]

40. Hu, J.; Lin, W.; Lin, B.; Wu, K.; Fan, H.; Yu, Y. Persistent DNA methylation changes in zebrafish following graphene quantum dots exposure in surface chemistry-dependent manner. *Ecotoxicol. Environ. Saf.* 2019, 169, 370–375. [CrossRef]

41. Rossner, P., Jr.; Vrbova, K.; Rossnerova, A.; Zavodna, T.; Milcova, A.; Klema, J.; Vecera, Z.; Mikuska, P.; Coufalik, P.; Capka, L.; et al. Gene Expression and Epigenetic Changes in Mice Following Inhalation of Copper(II) Oxide Nanoparticles. *Nanomaterials* 2020, 10, 550. [CrossRef]

42. Chen, J.; Bardes, E.E.; Aronow, B.J.; Jegga, A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. *Nucleic Acids Res.* 2009, 37, W305–W311. [CrossRef] [PubMed]

43. Vila-Casadesus, M.; Gironella, M.; Jose Lozano, J. MiRComb: An R Package to Analyse miRNA-mRNA Interactions. Examples across Five Digestive Cancers. *PLoS ONE* 2016, 11, e0151127. [CrossRef] [PubMed]

44. Maksimovic, J.; Phipson, B.; Oshlack, A. A cross-package Bioconductor workflow for analysing methylation array data. *F1000Research* 2016, 5, 1281. [CrossRef] [PubMed]